The Technical AnalystExchange: STO Sector: Healthcare Industry: Diagnostics & Research
Immunovia AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.84% SEK1.452
America/New_York / 17 mai 2024 @ 11:20
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 65.76 mill |
| EPS: | -5.17 |
| P/E: | -0.280 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 45.29 mill |
| Avg Daily Volume: | 0.751 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.280 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.280 | industry: PE 48.39 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK-0.294 (-120.22%) SEK-1.746 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 1.169 - 1.731 ( +/- 19.38%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK1.452 (-3.84% ) |
| Volume | 0.164 mill |
| Avg. Vol. | 0.751 mill |
| % of Avg. Vol | 21.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMMNOV.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IMMNOV.ST
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.